AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Verastem, Inc.
Video analysis: VSTM
All videosNo video analysis for this stock yet. Request one from our team.
News: VSTM
Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM
Bank of New York Mellon Corp acquired a new stake in shares of Verastem, Inc. (NASDAQ: VSTM) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 184,944 shares of the biopharmaceutical company's stock, valued at approximately $706,000.
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical upd.
Verastem Oncology to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET H.C. Wainwright Annual Global Investment Confer.
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform
Verastem is evolving from a speculative biotech into a commercially validated precision oncology company, leveraging AVMAPKI FAKZYNJA revenue to fund KRAS G12D programs. VSTM's AVMAPKI FAKZYNJA launch demonstrates strong product-market fit, with $43.7M H1 2026 revenue and growing prescriber adoption in a rare disease market. The October 2026 VS-7375 data update is a pivotal catalyst; positive results could unlock multibillion-dollar KRAS G12D markets in pancreatic, lung, and colorectal cancer.
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Verastem, Inc. (NASDAQ: VSTM - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has
Verastem Q2 Earnings Call Highlights
Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
